Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8(+) T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy

Oncolytic virotherapy has garnered attention as an antigen-agnostic therapeutic cancer vaccine that induces cancer-specific T cell responses without additional antigen loading. As anticancer immune responses are compromised by a lack of antigenicity and chronic immunosuppressive microenvironments, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Yun-Hui, Lee, Namhee, Yoo, Jiyoon, Won, Solchan, Shin, Suk-kyung, Kim, Kyu-Hwan, Park, Jun-Gyu, Kim, Min-Gang, Kim, Hang-Rae, Oh, Keunhee, Lee, Dong-Sup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027961/
https://www.ncbi.nlm.nih.gov/pubmed/35453555
http://dx.doi.org/10.3390/biomedicines10040805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027961/
https://www.ncbi.nlm.nih.gov/pubmed/35453555
http://dx.doi.org/10.3390/biomedicines10040805

Ejemplares similares